Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025

Reuters

10/07

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025

Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus $(HDV)$ infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573952408"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573952408\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573952408?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573952408","market":"us","top_or_hot":-1,"title":"Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-07 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL2tVpRb:1","article_id":"2573952408","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573952408","pubTimestamp":1759838438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on October 07, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","BK4139":"生物科技","BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"Vir Biotechnology将在2025年AASLD上展示Tobevibart和Elebsiran治疗慢性δ型肝炎的SOLSTICE 2期试验第48周的阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n    \n\n        Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus $(HDV)$ infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}